Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAZ-AVI in Chinese adults with HAP/VAP
NCT04774094Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP), sponsored by Pfizer. Started May 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT04774094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774094.